Cerebra, a Winnipeg, Canada-based sleep diagnostics company, has entered into a contract with the government of Manitoba under a request for supply arrangement for the provision of diagnostic services.
Through the arrangement, Cerebra will work closely with the Canadian province of Manitoba to reduce the backlog of diagnostic sleep studies caused by the COVID-19 pandemic. The contract is for one thousand in-home polysomnography studies and will begin in early 2023 using the Cerebra Sleep System. Referred patients will be able to perform a type II sleep study in the comfort of their homes.
“Bringing the sleep lab to the home has many benefits,” says Patrick Crampton, president and COO at Cerebra, in a release. “Combining the convenience of traditional in-home sleep apnea studies with the much more comprehensive sleep analysis of a PSG is a major step forward in expanding diagnostic capabilities for both patients and sleep specialists.
“Sleep is such a vital component for overall health. Undiagnosed sleep disorders can increase an individual’s risk of diabetes, obesity, hypertension, and heart disease. The pandemic has impacted sleep study wait lists much the same as other areas of our healthcare system. The opportunity to leverage locally developed technology to help Manitobans is a great example of the innovation ecosystem Manitoba is developing. We are honored and excited to begin helping Manitobans and these one thousand studies are a great start.”
